valsartan has been researched along with monocrotaline in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, W; Dong, J; Gao, D; Guo, H; Lu, Y; Pan, X; Sun, Y; Xu, D; Xu, Y | 1 |
| Hu, J; Liu, S; Liu, W; Lu, S; Wang, Y; Wang, Z; Zeng, X | 1 |
4 other study(ies) available for valsartan and monocrotaline
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Valsartan attenuates pulmonary hypertension via suppression of mitogen activated protein kinase signaling and matrix metalloproteinase expression in rodents.
Topics: Animals; Blood Pressure; Cell Proliferation; Extracellular Matrix; Fibrosis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; MAP Kinase Signaling System; Matrix Metalloproteinases; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Monocrotaline; Phosphorylation; Rats, Sprague-Dawley; Systole; Transforming Growth Factor beta1; Valsartan; Vascular Remodeling | 2017 |
Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Body Weight; Disease Models, Animal; Disease Progression; Drug Combinations; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan | 2021 |